deliver long-term benefit due to the emergence of resistant cells 1,2 . This is thought 33 to be the consequence of strong selective pressure exerted on the cancer drug 34 target by a Maximum Tolerated Dose (MTD) of a drug [3][4][5] . We hypothesized that 35 partial inhibition of multiple components in the same oncogenic signalling 36 pathway might add up to complete pathway inhibition, while at the same time 37 decreasing the selective pressure on each individual component to acquire a 38 resistance mutation. We report here testing of this Multiple Low Dose (MLD) 39 model of drug administration in Epidermal Growth Factor Receptor (EGFR) mutant 40 non-small cell lung cancer (NSCLC). We show that as little as 20% of the 41 individual drug doses required for full inhibition of cell viability is sufficient to 42 completely block MAPK signalling and proliferation when used in 3D 43 (RAF+MEK+ERK inhibitors) or 4D (EGFR+RAF+MEK+ERK inhibitors) 44 combinations. Importantly, EGFR mutant NSCLC cells treated with EGFR 45 inhibitors at a high dose rapidly developed resistance in vitro, but the cells treated 46
treatment is the result of an effect of these drugs on homeostatic feedback/cross-talk 179 signalling 25, 27 , as pulsatile signalling through the MAPK pathway seems to be much less 180 affected than persistent signalling through an oncogene-activated MAPK pathway. 181 To address if the MLD strategy is effective in vivo, we used patient derived 182 xenograft (PDX) tumours from four different patients who had developed resistance to 183 first-or second-line therapy with EGFR inhibitors erlotinib or osimertinib 6 in the clinic by 184 acquiring EGFR T790M mutation, KRAS mutation or MET amplification (Supplemental Table 2 ). For the in vivo studies we defined LD as 20-30% of the published maximum 8 tolerated dose (MTD) for each of the individual drugs 18, 19, 28, 29 . Osimertinib-resistant 187 PDX-1 was implanted subcutaneously and orthotopically in the lungs. In both models, 188 treatment with 3D or 4D combination resulted in a reduction in tumour volume, without 189 associated toxicity ( Fig. 4a-d ). Interestingly however, treatment with 4D combo was 190 slightly more effective than 3D combo. Due to this finding we focused the in vivo studies 191 that followed on the 4D combination. In all PDX models tested we observed similar 192 results to PDX-1, i.e., a reduction in tumour volume, without significant toxicity (Figs. 4e, 193 f and Supplemental Fig. 4e ). Additionally, in gefitinib-resistant models PDX-2 and PDX-3 194 we tested if it would be possible to acquire resistance to the 4D MLD combination 195 therapy during a drug holiday. In both PDX models, re-starting of 4D MLD therapy after 196 a drug holiday resulted in a second response to the drug combination, indicating that 197 overt resistance had not developed in vivo (Figs. 4e, f) . 198 We also implanted PC9 cells in nude mice and treated them with vehicle, with 199 EGFR, RAF, MEK and ERK inhibitors individually at low dose and with 4D combination.
200
The use of low dose regimens was inadequate to suppress PC9 tumour growth when 201 used as single agents, but when used in combination we observed a sustained 202 reduction in the tumour volume of PC9 xenografts over a period of 70 days, which was 203 associated with an extended survival (Supplemental Fig. 4a, b ). These observations are 204 also supported by immunohistochemical staining of the tumours, which show decreased 205 Ki67 (a proliferation marker) and pERK (MAPK activation) levels in the tumours treated 206 with 4D combination (Fig. 4g ). Significantly, mice treated with 4D combination did not 207 show any significant signs of toxicity, assessed by the weight of the mice over time and 208 by the morphology of the GI tract and bone marrow (Supplemental Figs. 4c, f) . In the 209 clinic, the T790M mutation is already present (at very low percentages) in the majority of 210 the tumours before undergoing anti-EGFR treatment 30,31 . To mimic this scenario, we 211 implanted in nude mice a mix of PC9 cells and PC9 GR cells (which are T790M positive) 212 in a 9:1 ratio, respectively. Mice were treated with vehicle, with MTD of gefitinib and with 213 4D combination. Treatment with MTD of gefitinib resulted in a quick reduction of tumour 214 volume which was followed by outgrowth of resistant cells, unlike the mice treated with Despite the significant tumour regressions observed in the in vivo experiments none of the mice were fully cured, unlike in the in vitro data where all the cells were 219 killed by the 3D or 4D combinations. To study why this is the case we studied the 220 pharmacokinetics and pharmacodynamics of the four drugs in vivo over time. We found 221 that drug plasma concentrations of gefitinib and trametinib dropped relatively slowly (T 1/2 222 8 hours), but the pan-RAF and ERK inhibitors were less stable in plasma (T 1/2 of 5 and 4 223 hours, respectively). A similar difference was seen for intra-tumoural drug concentrations 224 (Supplemental Figs. 5a, b) . Consistent with this, we observed a complete inhibition of 225 pRSK in tumour biopsies two hours after 4D combination drug administration, which 226 progressively decreased after 8 and 24 hours (Supplemental Fig. 5c ). These data 227 indicate that, unlike in the in vitro experiments, two of the four drugs were not present at 228 a significant concentration during at least 12 hours of the 24-hour treatment cycle. As a 229 result of this, a sustained MAPK pathway inhibition was not achieved in vivo, possibly 230 explaining why we didn't achieve full tumour regressions. We tested this hypothesis in 231 vitro, by removing RAF and ERK inhibitors from the treatment for approximately 8 hours 232 every day. We found that, as hypothesized, when the drugs in the 3D or 4D combination 233 were not present continuously the MLD therapy became less effective (Supplemental 234 Fig. 5d ).
236
We report here that treatment of EGFR mutant NSCLCs with MLD therapy 237 effectively suppresses development of drug resistance, without associated toxicity. As Importantly, we show that tumours having the most common mechanisms of 248 clinically-observed resistance to high dose standard of care EGFR inhibitors still respond 249 to MLD therapy. Therefore, MLD treatment strategy appears especially promising for 250 patients that have already developed resistance to all clinically used EGFR inhibitors, 251 including osimertinib. In such resistant tumours, multiple metastases may be present 252 having different resistance mutations. In this study we have shown that MLD therapy is 253 effective in PDX models having diverse EGFR inhibitor resistance mechanisms, 254 including EGFR T790M mutation, KRAS mutation and MET amplification, highlighting 255 that MLD therapy could apply to a diverse range of EGFR TKI resistant tumours. Indeed, 256 in clinical practice, an MLD treatment strategy can only be tested in patients having 257 developed resistance to standard-of-care EGFR inhibitors. We find in PDX models that 258 4D MLD is consistently somewhat better than 3D MLD, which may relate to the notion 259 that not all EGFR alleles in the tumour may have acquired resistance mutations to the 260 EGFR inhibitor therapy. Furthermore, it will be important to maintain osimertinib in an 261 experimental MLD therapy trial, as this drug crosses the blood-brain barrier, and such 262 late-stage patients may have (latent) brain metastases. We therefore suggest that 263 clinical testing of the MLD strategy should include osimertinib.
264
While we never observed development of resistance to MLD therapy in vivo, even 265 after long drug exposure, we did not achieve complete tumour regressions. This is most 266 likely due to the short half-lives of the RAF and ERK inhibitors used in this study, which 267 resulted in a situation in which we did not achieve a continuous pathway blockade. This 268 may be improved by using continuous release formulations of these drugs, or by using 269 drugs with longer half-lives.
270
The MLD therapy described here is fundamentally different from metronomic 271 chemotherapy 32,33 . In this latter scenario, low doses of chemotherapy are given at high The lack of significant toxicity of the MLD therapy may be explained by the 279 fundamentally different nature of MAPK pathway signalling between normal and EGFR 280 mutant cancer cells. In the former, signalling is transiently activated when growth factors 281 are present. In the latter, oncogenic mutations result in persistent activation of the 282 pathway. Importantly, we show here that transient signalling in normal cells is, at least 283 initially, not interrupted by MLD treatment (Fig. 3c ). This may explain why long-term 284 exposure of mice to MLD treatment is without major toxicity, as judged by lack of weight 285 loss and lack of toxicity to gut epithelium and bone marrow.
286
Even though we focused mostly on EGFR mutant NSCLC, we have also shown 287 that the MLD strategy can potentially be effective in other tumour types. Overall, our 288 findings challenge the current paradigm of using the maximum tolerated dose of single 289 targeted cancer drugs and suggest that, instead, it might be more beneficial to use a 290 combination of multiple drugs that target the oncogenically activated pathway using sub-291 optimal drug concentrations.
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